drugset / Trial / NCT04301011
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).
Timeline
- Start
- 2020-06-02
- Primary completion
- 2023-01-23
- Completion
- 2023-01-23
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | TBio-6517 | Unknown | — | Other |